Ergotamine

26 interactions 1 explained in plain English
Also sold as: Ergomar
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Major

Ergotamine Abametapir Explained Increased exposure of CYP3A4 substrate Details Ergotamine Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Ergotamine Azithromycin AzaSite An increased risk of acute ergot toxicity (ergotism) Details Ergotamine Clotrimazole Aardora Anti-Fungal Maximum Strength Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ergotamine Clotrimazole Lozenge Mycelex® Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ergotamine Clotrimazole Topical Cruex Antifungal Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ergotamine Clotrimazole Vaginal Gyne-Lotrimin 3® Cream Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ergotamine Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Ergotamine Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Ergotamine Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Ergotamine Lenacapavir Injection Sunlenca Increased ergotamine exposure Details Ergotamine Lenacapavir Oral Sunlenca Increased ergotamine exposure Details Ergotamine Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Ergotamine Nevirapine Viramune Reduced ergotamine exposure Details Ergotamine Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Ergotamine Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.